MOONLAKE IMMUNOTHERAPEUTICS Debt Securities, Available-for-sale, Amortized Cost
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) had Debt Securities, Available-for-sale, Amortized Cost of $58.75 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-10
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $58.75M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $59.07M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $59.17M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $29.26M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost | Debt Securities, Available-for-sale, Amortized Cost as first filed |
|---|---|---|
| 2026-06-30 | $58.75M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $59.07M 10-Q · filed 2026-05-11 | |
| 2025-12-31 | $59.17M 10-Q · filed 2026-08-10 | |
| 2025-09-30 | $29.26M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $117.66M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $205.91M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $321.88M 10-K · filed 2026-02-25 | $321.88M 10-K · filed 2025-02-26 |
| 2024-09-30 | $174.83M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $233.39M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $275.25M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $186.51M 10-K · filed 2025-02-26 | |
| 2023-09-30 | $294.11M 10-Q · filed 2023-11-14 | |
| 2023-03-31 | $47.28M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $52.10M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $62.12M 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |